psmarketresearch1’s blog

All about market research update

Air Quality Monitoring Market Growth Drivers, Trends and Future Scope

f:id:vijaymishrapsmarket1:20180515190142j:plain

The AQM market is primarily driven by increasing level of air pollution across the globe, increasing awareness regarding environmental and healthcare implications of air pollution and favorable government regulations for AQM.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/air-quality-monitoring-devices-market/report-sample

In terms of product type, the AQM market has been segmented into indoor air quality monitor and outdoor air quality monitor. The indoor monitor accounted for the major share in the global market in 2015, whereas the outdoor monitor market is expected to witness the highest growth during 2016 – 2022.

In terms of pollutant type, the AQM market has been segmented into chemical pollutant, biological pollutant and physical pollutant. The chemical pollutant segment accounted for the major share in the global market in 2015, and it is also expected to witness the highest growth during 2016 – 2022.

Explore Report at: https://www.psmarketresearch.com/market-analysis/air-quality-monitoring-devices-market

Some of the major players operating in the AQM market include Thermo Fisher Scientific Inc., Merck KGaA, Teledyne Technologies Incorporated, HORIBA, Ltd., Emerson Electric Co., General Electric Company, TSI Incorporated, 3M Company, and Siemens AG.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

 

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Amyotrophic Lateral Sclerosis Pipeline Analysis 2017 - Clinical Trials & Results, Patent and Other Developments

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 69 drug candidates, of which one drug candidate is in Phase III stage, 16 drug candidates are in Phase II stage, nine drug candidates are in Phase I stage, 32 drug candidates are in Pre-Clinical stage, five candidates are inactive and six drug candidates are in discontinued stage. Amyotrophic lateral sclerosis is a neurodegenerative disorder in brain and spinal cord, the progression of the disease can further lead to muscles getting enough nourishments, which can further cause atrophy of the muscles. Amyotrophic Lateral Sclerosis occurs mostly in the lateral region of the body, in which spinal cord reflexes are too intense. This can also lead to scarring and hardening of the muscles into that region. Various new therapies and advanced technologies are driving the growth of Amyotrophic lateral sclerosis pipeline.

Explore Report Overview at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

As per the findings of the research, around 31.0% of drug candidates for the treatment of amyotrophic lateral sclerosis pipeline are being developed to be administered by oral route, 4.0% by intravenous route, 48.0% are not disclosed and 17.0% are to be administered by other routes which includes subcutaneous, intraperitoneal, sublingual, inhalation and intramuscular.

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan. Dainippon Sumitomo Pharma Co., Ltd. received exclusive research, development and commercial rights in Japan for EPI-743 and EPI-589. Edison Pharmaceuticals, Inc. received $35.0 million in an upfront payment and $15.0 million as research and development support fee. In addition, Edison Pharmaceuticals, Inc. also received $10.0 to $35.0 million in milestone payments per indication associated with successful development. After the launch, Edison Pharmaceuticals, Inc. received royalties based on sales amounts and up to $460.0 million in milestone payments in accordance with sales goals.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample

Many companies are developing Amyotrophic lateral sclerosis drug candidates in different phases. Cytokinetics, Inc., AB Science, F. Hoffman La-Roche AG, FlexPharma, Inc., Orion Corporation, Omeros Corporation, Genervon Biopharmaceuticals, LLC, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and various other companies have their Amyotrophic lateral sclerosis drug candidates in different stages of development. Cytokinetics, Inc. has drug candidate in Phase III clinical stage.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, Orphazyme ApS, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and Cytokinetics, Inc.

Healthcare BPO Market Analysis, Size, Development, Growth and Forecast to 2023

f:id:vijaymishrapsmarket1:20170619202234j:plain

The global healthcare business process outsourcing market is witnessing significant growth, due to technological advancements in healthcare IT sector and increasing demand for reducing healthcare costs. The tenth revision of International Statistical Classification of Diseases and Health Related Problems (ICD-10), emergence of biologics and massive unexplored healthcare BPO market in the emerging economies are creating ample opportunities for the growth of the global healthcare BPO market. Healthcare reforms across the globe and adoption of healthcare BPO by major pharmaceuticals, biopharmaceuticals and biotechnology companies are supporting the demand of cost effective and improved healthcare system.

Explore more About Healthcare BPO Market at: https://www.psmarketresearch.com/market-analysis/healthcare-bpo-market

Healthcare BPO is the practice of outsourcing business operations by healthcare providers, payers and organizations. Healthcare BPO has several advantages, such as availability of skilled workforce at low cost, reduction in training and administrative costs, and high profitability for healthcare organizations, payers, and providers. In addition, healthcare BPO also improves the quality of patient care, while reducing the investment required for infrastructure.

The global healthcare BPO market is segmented into pharmaceuticals outsourcing, providers outsourcing, and payers outsourcing. The pharmaceutical outsourcing segment leads the global healthcare BPO market. The pharmaceuticals outsourcing segment can be further categorized as contract manufacturing organizations (CMO), contract research organizations (CRO) and non-clinical services. The healthcare providers outsourcing segment includes medical transcription, medical billing, medical coding, and finance and accounts. The healthcare payers outsourcing segment includes customer care and member services, HR services, claims processing, and finance and accounts.

Some of the factors driving the growth of the global healthcare BPO market are increasing healthcare costs, advancement in the healthcare IT technology, lack of skilled professionals and increasing demand for improved healthcare. In addition, the high cost associated with R&D and manufacturing of drugs and reduced productivity is compelling the major pharmaceuticals companies to outsource their business processes. However, data security and privacy concerns, unforeseen costs, and difference in the regulatory processes within different countries are restraining the growth of the global healthcare BPO market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/healthcare-bpo-market/toc-sample

Some of the major players operating in the global healthcare BPO market are Accenture, Tata Consultancy Services (a part of Tata Group), Genpact, Boehringer Ingelheim GmbH, Cognizant, Charles River Laboratories International Inc., Covance Inc., Infosys Limited, Lonza Group Ltd. and Quintiles Inc.

Graves Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results and Other Developments

Graves disease therapeutic pipeline analysis is expected to increase owing to the high prevalence of the disease. Growing number of cases for hyperthyroidism is a major factor driving the pipeline analysis for Graves disease . In addition, increasing awareness regarding health issues among people is another major factor contributing towards the pipeline for Graves disease. According to American Thyroid Association, the prevalence of Graves disease has increased with increasing hyperthyroidism patients.

Explore Report at: https://www.psmarketresearch.com/market-analysis/graves-disease-therapeutics-pipeline-analysis

Graves disease is the result of hyperthyroidism, which basically means overproduction of thyroid gland. Hyperthyroidism cause majority of symptoms of Graves disease and it can also be associated with eyes inflammation, swelling of the tissues around the eyes and eyes bulging known as Graves ophthalmopathy. The most common symptoms of Graves disease include eye disease and skin disease. Eye disease includes redness of eyes and irritation of the eyes while skin disease includes pretibial myxedema in which a reddish lump is formed in front of the shins. The other symptoms of Graves disease are weight loss, anxiety, erectile dysfunction, change in menstrual cycles, irregular heartbeat and bulging eyes. Graves disease is an autoimmune disease in which antibodies bind to thyroid cells which results in overproduction of thyroid hormones. This results in hyperthyroidism. Graves disease is diagnosed by clinical observation and confirmed by laboratory testing which includes measuring thyroid hormone (thyroxine, or T4, and triiodothyronine, or T3) and thyroid-stimulating hormone (TSH) in patient’s blood. Also family history with thyroid or autoimmune diseases is analyzed. Some of the risk factors of Graves disease include age, family history, smoking, pregnancy and autoimmune disorders. Treatment includes anti-thyroid medications, beta blockers and surgery. It is treated using antithyroid drugs including methimazole [Tapazole] and surgery in severe cases.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/graves-disease-therapeutics-pipeline-analysis/toc-sample

Some of the key companies having a pipeline of Graves disease therapeutics include AV7 Limited, Apitope International NV, Neothetics, Inc., Nova Therapeutics LLC, Novartis AG, Omeros Corp. and Rodos BioTarget GmbH.

Ulcerative Colitis Therapeutics Pipeline Analysis 2017 — Clinical Trials & Results, and Other Developments

The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates, of which 68 drug candidates are in active stage. Among the active drug candidates, one drug is in NDA filed stage, 11 are in Phase III stage, 28 are in Phase II stage, 13 are in Phase I stage, 14 are in Pre-Clinical stage and one drug is in Discovery stage of development. The development of 18 ulcerative colitis drug candidates is found to be inactive and three drug candidates are discontinued.

Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators. The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab.

Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis

Pipeline Insights

The pipeline for ulcerative colitis was analyzed based on route of administration, molecule type and phase of drugs. Based on route of administration, around 46.0% of the active pipeline drug candidates of ulcerative colitis are being developed to be administered by oral route and 29.0% by are being developed to be administered by intravenous and subcutaneous route. Approximately 3.0% drug candidate are being administered by parenteral route, and 4.0% drug candidates are administered by intravenous; subcutaneous route. The route of administration of 29.0% drug candidates is undisclosed. The route of administration of 18.0% drug candidates are being administered by intravenous infusion, rectal, topical and others.

Several pharmaceutical companies engaged in the development of the ulcerative colitis drug candidates include, but are not limited to, Novartis Pharmaceuticals, EA Pharma Co., Ltd., Celgene Corporation, Galapagos NV, Lipid Therapeutics GmbH, and Momenta Pharmaceuticals, Inc.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB, F. Hoffman-La Roche AG, Sigmoid Pharma Ltd., Pfizer, Inc., Momenta Pharmaceuticals, Inc., Johnson & Johnson, Arena Pharmaceuticals, Inc., and Novartis AG.

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis, 2017

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

Insights on pipeline analysis

As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.

 

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.

Automotive Sunroof Market Trends, Size, Development and Forecast to 2022

f:id:vijaymishrapsmarket1:20170503034558j:plain

The global automotive sunroof market was valued at $4,924.5 million in 2015, and it is expected to grow at a CAGR of 10.9% during 2016 - 2022. The factors driving the growth of the global market includes growing need to control light inside vehicle, growing demand for premium cars, and greater glass surface area in automobiles, including larger sunroofs. Additionally, the development of technology for reducing cost and expanding functionality of sunroof glasses and increasing consumer preference towards automotive sunroof vehicles in developing nations are expected to further propel the global demand of automotive sunroof.

Explore Full Market Research Report at: https://www.psmarketresearch.com/market-analysis/automotive-sunroof-market

Automotive sunroof refers to any roof opening in vehicle, such as one with a retractable metal panel. Modern sunroof consists of around 200 parts, and vehicle maker now use them and other roof system to help differentiate product offering to customers. Consumers now expect an increasingly high level of comfort in their cars, particularly where air conditioning and sun roof are concerned. Such equipment is no longer the exclusive domain of luxury cars. As the market is becoming increasingly competitive, vehicle makers are using sunroofs and other roof systems to help differentiate the product offering to customers. The demand for sunroof as an after sales market has also contributed to the growth of the global automotive sunroof market. The growing alternative fuel vehicle segments have forced the automotive innovators to develop sunroofs with built-in solar cells, which provide power to vehicles. The preference of car involving a sunroof is a major trend witnessed in the automotive sunroof market during the last few years.

Among the various vehicle types, the premium cars held the major market share in the global automotive sunroof market. The high-income group prefers premium cars owing to their aesthetic looks, convenient travel experience, and it also resembles the statues symbol in the society. Now-a-days sedan cars are extensively using sunroof systems, as the manufacturer are targeting middle income group people and also the convertible sunroofs are gaining popularity among the individuals. Thus, the sedan car segment is expected to witness the fastest growth in the global automotive sunroof market during the forecast period.

Request for Sample Pages: https://www.psmarketresearch.com/market-analysis/automotive-sunroof-market/report-sample

Some of the major companies operating in the global automotive sunroof market include Webasto SE, Johnan America, Inc., Automotive Sunroof Company, Nippon Sheet Glass Co. Ltd., Yachiyo Industry Co., Ltd., Corning Inc., Meritor Inc., Aisin Seiki Co., Ltd., Inteva Products, LLC, and Inalfa Roof Systems Group B.V.